Monopar Therapeutics (MNPR) Cash & Equivalents Growth (5y) (2021 - 2026)

Monopar Therapeutics (MNPR) Cash & Equivalents Growth (5y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Monopar Therapeutics 965.64 Mn 912.88 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2026 16.78%
Dec 31, 2025 30.07%
Sep 30, 2025 48.00%
Jun 30, 2025 25.78%
Mar 31, 2025 25.82%
Dec 31, 2024 28.23%
Sep 30, 2024 6.02%
Jun 30, 2024 3.59%
Mar 31, 2024 5.83%
Dec 31, 2023 1.06%
Sep 30, 2023 -6.26%
Jun 30, 2023 -2.57%
Mar 31, 2023 3.04%
Dec 31, 2022 -3.50%
Sep 30, 2022 5.63%
Jun 30, 2022 30.91%
Mar 31, 2022 38.07%
Dec 31, 2021 47.43%